Literature DB >> 10930666

Mutations occurring during serial passage of Japanese equine infectious anemia virus in primary horse macrophages.

Y H Zheng1, H Sentsui, Y Kono, K Ikuta.   

Abstract

An attenuated equine infectious anemia virus (EIAV), named V26, was previously obtained after 50 passages of the Japanese virulent strain V70 in primary macrophage culture. To clarify the differences between both viruses, their full-length sequences were determined. There were higher mutations in S2 (6.15% amino acid difference) and LTR (10.7% nucleotide difference). The presumed initiation codon of the S2 gene was absent from the sequence of V26. There was a large insertion within the long-terminal repeat (LTR) U3 hypervariable region of V26. In addition, there were minor mutations in gag (1.22% amino acid difference), pol (1.05% amino acid difference) and env (1. 65% amino acid difference) regions, but no mutation in tat region. No mutations were observed in the principal neutralizing domain in the gp90. Thus, the mutations in the S2 and LTR might be the major target sites of mutation in EIAV during serial passages in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930666     DOI: 10.1016/s0168-1702(00)00147-7

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

1.  Antibody escape kinetics of equine infectious anemia virus infection of horses.

Authors:  Elissa J Schwartz; Seema Nanda; Robert H Mealey
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

3.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  The retroviral accessory proteins S2, Nef, and glycoMA use similar mechanisms for antagonizing the host restriction factor SERINC5.

Authors:  Iqbal Ahmad; Sunan Li; Rongrong Li; Qingqing Chai; Lixin Zhang; Bin Wang; Changqing Yu; Yong-Hui Zheng
Journal:  J Biol Chem       Date:  2019-03-12       Impact factor: 5.157

5.  Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.

Authors:  Xiue Han; Ping Zhang; Wei Yu; Wenhua Xiang; Xiaodong Li
Journal:  Virus Genes       Date:  2016-08-29       Impact factor: 2.332

6.  In silico segmentations of lentivirus envelope sequences.

Authors:  Aurélia Boissin-Quillon; Didier Piau; Caroline Leroux
Journal:  BMC Bioinformatics       Date:  2007-03-21       Impact factor: 3.169

7.  Comprehensive analysis of the overall codon usage patterns in equine infectious anemia virus.

Authors:  Xin Yin; Yuezhi Lin; Weigang Cai; Ping Wei; Xiaojun Wang
Journal:  Virol J       Date:  2013-12-20       Impact factor: 4.099

Review 8.  Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.

Authors:  Jodi K Craigo; Ronald C Montelaro
Journal:  Viruses       Date:  2013-12-02       Impact factor: 5.048

9.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602

10.  Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo.

Authors:  Xue-Feng Wang; Qiang Liu; Yu-Hong Wang; Shuai Wang; Jie Chen; Yue-Zhi Lin; Jian Ma; Jian-Hua Zhou; Xiaojun Wang
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.